Nội dung được dịch bởi AI, chỉ mang tính chất tham khảo

Ung thư tuyến tiền liệt, Phiên bản 2.2019, Hướng dẫn Thực hành Lâm sàng NCCN trong Ung thư học

Journal of the National Comprehensive Cancer Network : JNCCN - Tập 17 Số 5 - Trang 479-505 - 2019

James L. Mohler¹, Emmanuel S. Antonarakis², Andrew J. Armstrong³, Anthony V. D’Amico⁴, Brian J. Davis⁵, Tanya B. Dorff⁶, James A. Eastham⁷, Charles A. Enke⁸, Thomas A. Farrington⁹, Celestia S. Higano¹⁰, Eric M. Horwitz¹¹, Michael E. Hurwitz^12,13, Joseph E. Ippolito¹⁴, Christopher J. Kane¹⁵, Michael Kuettel¹, Joshua M. Lang¹⁶, Jesse K. McKenney¹⁷, George J. Netto¹⁸, David F. Penson¹⁹, Elizabeth R. Plimack¹¹, Julio M. Pow‐Sang²⁰, Thomas J. Pugh²¹, Sylvia Richey²², Mack Roach²³, Stan Rosenfeld²³, Edward M. Schaeffer²⁴, Ahmad Shabsigh²⁵, Eric J. Small²³, Daniel E. Spratt²⁶, Sandy Srinivas²⁷, Jonathan D. Tward²⁸, Dorothy A. Shead²⁹, Deborah A. Freedman-Cass²⁹

¹1Roswell Park Comprehensive Cancer Center;

²2The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;

³3Duke Cancer Institute;

⁴4Dana-Farber/Brigham and Women’s Cancer Center;

⁵5Mayo Clinic Cancer Center;

⁶6City of Hope National Cancer Center;

⁷7Memorial Sloan Kettering Cancer Center;

⁸8Fred & Pamela Buffett Cancer Center;

⁹9Prostate Health Education Network (PHEN);

¹⁰10Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance;

¹¹11Fox Chase Cancer Center;

¹²12Yale Cancer Center/Smilow Cancer Hospital;

¹³Yale Cancer Center/

¹⁴13Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine;

¹⁵14UC San Diego Moores Cancer Center;

¹⁶15University of Wisconsin Carbone Cancer Center;

¹⁷16Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute;

¹⁸University of Alabama at Birmingham Comprehensive Cancer Center; 18 Vanderbilt-Ingram Cancer Center;

¹⁹18Vanderbilt-Ingram Cancer Center;

²⁰19Moffitt Cancer Center;

²¹20University of Colorado Cancer Center;

²²21St. Jude Children’s Research Hospital/The University of Tennessee Health Science Center;

²³22UCSF Helen Diller Family Comprehensive Cancer Center;

²⁴23Robert H. Lurie Comprehensive Cancer Center of Northwestern University;

²⁵24The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute;

²⁶25University of Michigan Rogel Cancer Center;

²⁷26Stanford Cancer Institute;

²⁸27Huntsman Cancer Institute at the University of Utah; and

²⁹28National Comprehensive Cancer Network

Tóm tắt

Các Hướng dẫn NCCN cho Ung thư tuyến tiền liệt bao gồm các khuyến cáo liên quan đến chẩn đoán, phân loại nguy cơ và quy trình công việc, các lựa chọn điều trị cho bệnh lý khu trú, cũng như quản lý bệnh tái phát và bệnh tiến triển cho các bác sĩ lâm sàng điều trị bệnh nhân mắc ung thư tuyến tiền liệt. Các phần của hướng dẫn được trình bày ở đây tập trung vào vai trò của xét nghiệm gen di truyền và gen somatic, phân loại nguy cơ với các biểu đồ nomogram và xét nghiệm đa gen khối u, liệu pháp ức chế androgen, liệu pháp hormone thứ phát, hóa trị và liệu pháp miễn dịch cho bệnh nhân ung thư tuyến tiền liệt.

Từ khóa

Tài liệu tham khảo

Briganti, 2007, A nomogram for staging of exclusive nonobturator lymph node metastases in men with localized prostate cancer, Eur Urol, 51, 112, 10.1016/j.eururo.2006.05.045

Magi-Galluzzi, 2018, The 17-gene genomic prostate score assay predicts outcome after radical prostatectomy independent of PTEN status, Urology, 121, 132, 10.1016/j.urology.2018.07.018

D’Amico, 2002, Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era, Cancer, 95, 281, 10.1002/cncr.10657

Imyanitov, 2011, Drug therapy for hereditary cancers, Hered Cancer Clin Pract, 9, 5, 10.1186/1897-4287-9-5

Gilbert, 2017, Quality-of-life outcomes from the Prostate Adenocarcinoma: TransCutaneous Hormones (PATCH) trial evaluating luteinising hormone-releasing hormone agonists versus transdermal oestradiol for androgen suppression in advanced prostate cancer, BJU Int, 119, 667, 10.1111/bju.13687

Moran, 2012, Risk of cancer other than breast or ovarian in individuals with BRCA1 and BRCA2 mutations, Fam Cancer, 11, 235, 10.1007/s10689-011-9506-2

Tryggvadóttir, 2007, Prostate cancer progression and survival in BRCA2 mutation carriers, J Natl Cancer Inst, 99, 929, 10.1093/jnci/djm005

Cooperberg, 2013, Validation of a cell-cycle progression gene panel to improve risk stratification in a contemporary prostatectomy cohort, J Clin Oncol, 31, 1428, 10.1200/JCO.2012.46.4396

Giri, Inherited mutations in men undergoing multigene panel testing for prostate cancer: emerging implications for personalized prostate cancer genetic evaluation [published online May 4, 2017], JCO Precision Oncol

Trachtenberg, 2002, A phase 3, multicenter, open label, randomized study of abarelix versus leuprolide plus daily antiandrogen in men with prostate cancer, J Urol, 167, 1670, 10.1097/00005392-200204000-00021

Ross, 2014, A genomic classifier predicting metastatic disease progression in men with biochemical recurrence after prostatectomy, Prostate Cancer Prostatic Dis, 17, 64, 10.1038/pcan.2013.49

Halpern, 2017, National trends in prostate biopsy and radical prostatectomy volumes following the US Preventive Services Task Force guidelines against prostate-specific antigen screening, JAMA Surg, 152, 192, 10.1001/jamasurg.2016.3987

Cuzick, 2011, Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study, Lancet Oncol, 12, 245, 10.1016/S1470-2045(10)70295-3

Holzbeierlein, 2004, Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance, Am J Pathol, 164, 217, 10.1016/S0002-9440(10)63112-4

Sweeney, 2015, Chemohormonal therapy in metastatic hormone-sensitive prostate cancer, N Engl J Med, 373, 737, 10.1056/NEJMoa1503747

Sun, 2016, Comparison of gonadotropin-releasing hormone agonists and orchiectomy: effects of androgen-deprivation therapy, JAMA Oncol, 2, 500, 10.1001/jamaoncol.2015.4917

Beer, 2017, Enzalutamide in men with chemotherapy-naive metastatic castration-resistant prostate cancer: extended analysis of the phase 3 PREVAIL study, Eur Urol, 71, 151, 10.1016/j.eururo.2016.07.032

Cullen, 2015, A biopsy-based 17-gene genomic prostate score predicts recurrence after radical prostatectomy and adverse surgical pathology in a racially diverse population of men with clinically low- and intermediate-risk prostate cancer, Eur Urol, 68, 123, 10.1016/j.eururo.2014.11.030

Stein, 2018, Randomized phase 2 therapeutic equivalence study of abiraterone acetate fine particle formulation vs originator abiraterone acetate in patients with metastatic castration-resistant prostate cancer: the STAAR study, Urol Oncol, 10.1016/j.urolonc.2017.10.018

Zelefsky, 2007, Pretreatment nomogram predicting ten-year biochemical outcome of three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for prostate cancer, Urology, 70, 283, 10.1016/j.urology.2007.03.060

Oudard, 2017, Cabazitaxel versus docetaxel as first-line therapy for patients with metastatic castration-resistant prostate cancer: a randomized phase III trial-FIRSTANA, J Clin Oncol, 35, 3189, 10.1200/JCO.2016.72.1068

Lecarpentier, 2017, Prediction of breast and prostate cancer risks in male BRCA1 and BRCA2 mutation carriers using polygenic risk scores, J Clin Oncol, 35, 2240, 10.1200/JCO.2016.69.4935

Tulinius, 2002, The effect of a single BRCA2 mutation on cancer in Iceland, J Med Genet, 39, 457, 10.1136/jmg.39.7.457

Taylor, 2017, Germline BRCA2 mutations drive prostate cancers with distinct evolutionary trajectories, Nat Commun, 8, 13671, 10.1038/ncomms13671

Middha, Reliable pan-cancer microsatellite instability assessment by using targeted next-generation sequencing data [published online October 3, 2017], JCO Precis Oncol.

James, 2016, Clinical outcomes and survival following treatment of metastatic castrate-refractory prostate cancer with docetaxel alone or with strontium-89, zoledronic acid, or both: The trapeze randomized clinical trial, JAMA Oncol, 2, 493, 10.1001/jamaoncol.2015.5570

Abdollah, 2014, Predicting survival of patients with node-positive prostate cancer following multimodal treatment, Eur Urol, 65, 554, 10.1016/j.eururo.2013.09.025

Narod, 2008, Rapid progression of prostate cancer in men with a BRCA2 mutation, Br J Cancer, 99, 371, 10.1038/sj.bjc.6604453

Potosky, 2014, Effectiveness of primary androgen-deprivation therapy for clinically localized prostate cancer, J Clin Oncol, 32, 1324, 10.1200/JCO.2013.52.5782

Siegel, 2017, Cancer Statistics, 2017, CA Cancer J Clin, 67, 7, 10.3322/caac.21387

Abida, Analysis of the prevalence of microsatellite instability in prostate cancer and response to immune checkpoint blockade [published online December 27, 2018], JAMA Oncol.

Borque, 2014, Implementing the use of nomograms by choosing threshold points in predictive models: 2012 updated Partin Tables vs a European predictive nomogram for organ-confined disease in prostate cancer, BJU Int, 113, 878, 10.1111/bju.12532

Böttcher, 2018, Cribriform and intraductal prostate cancer are associated with increased genomic instability and distinct genomic alterations, BMC Cancer, 18, 8, 10.1186/s12885-017-3976-z

Liede, 2004, Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2: a review of the literature, J Clin Oncol, 22, 735, 10.1200/JCO.2004.05.055

Pritchard, 2016, Inherited DNA-repair gene mutations in men with metastatic prostate cancer, N Engl J Med, 375, 443, 10.1056/NEJMoa1603144

Kattan, 2003, Counseling men with prostate cancer: a nomogram for predicting the presence of small, moderately differentiated, confined tumors, J Urol, 170, 1792, 10.1097/01.ju.0000091806.70171.41

Ryan, 2013, Abiraterone in metastatic prostate cancer without previous chemotherapy, N Engl J Med, 368, 138, 10.1056/NEJMoa1209096

Cher, 2017, Appropriateness criteria for active surveillance of prostate cancer, J Urol, 197, 67, 10.1016/j.juro.2016.07.005

Sammon, 2015, Prostate-specific antigen screening after 2012 US Preventive Services Task Force recommendations, JAMA, 314, 2077, 10.1001/jama.2015.7273

Etzioni, 2016, Recent trends in PSA testing and prostate cancer incidence: a look at context, JAMA Oncol, 2, 955, 10.1001/jamaoncol.2015.6310

Makarov, 2007, Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005, Urology, 69, 1095, 10.1016/j.urology.2007.03.042

Blume-Jensen, 2015, Development and clinical validation of an in situ biopsy-based multimarker assay for risk stratification in prostate cancer, Clin Cancer Res, 21, 2591, 10.1158/1078-0432.CCR-14-2603

Graff, 2016, Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer, Oncotarget, 7, 52810, 10.18632/oncotarget.10547

Ross, 2016, Tissue-based genomics augments post-prostatectomy risk stratification in a natural history cohort of intermediate- and high-risk men, Eur Urol, 69, 157, 10.1016/j.eururo.2015.05.042

Berthold, 2008, Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study, J Clin Oncol, 26, 242, 10.1200/JCO.2007.12.4008

Herget, 2016, Recent decline in prostate cancer incidence in the United States, by age, stage, and Gleason score, Cancer Med, 5, 136, 10.1002/cam4.549

Mersch, 2015, Cancers associated with BRCA1 and BRCA2 mutations other than breast and ovarian, Cancer, 121, 269, 10.1002/cncr.29041

Leapman, 2017, Application of a prognostic Gleason grade grouping system to assess distant prostate cancer outcomes, Eur Urol, 71, 750, 10.1016/j.eururo.2016.11.032

Albertsen, 2014, Cardiovascular morbidity associated with gonadotropin releasing hormone agonists and an antagonist, Eur Urol, 65, 565, 10.1016/j.eururo.2013.10.032

Risbridger, 2015, Patient-derived xenografts reveal that intraductal carcinoma of the prostate is a prominent pathology in BRCA2 mutation carriers with prostate cancer and correlates with poor prognosis, Eur Urol, 67, 496, 10.1016/j.eururo.2014.08.007

Gandaglia, 2017, Are all grade group 4 prostate cancers created equal? Implications for the applicability of the novel grade grouping, Urol Oncol, 35, 461.e7, 10.1016/j.urolonc.2017.02.012

Siegel, 2019, Cancer statistics, 2019, CA Cancer J Clin, 69, 7, 10.3322/caac.21551

Labrie, 1987, Flutamide eliminates the risk of disease flare in prostatic cancer patients treated with a luteinizing hormone-releasing hormone agonist, J Urol, 138, 804, 10.1016/S0022-5347(17)43380-5

Ryan, 2013, Abiraterone in metastatic prostate cancer without previous chemotherapy, N Engl J Med, 368, 138, 10.1056/NEJMoa1209096

Kantoff, 2010, Sipuleucel-T immunotherapy for castration-resistant prostate cancer, N Engl J Med, 363, 411, 10.1056/NEJMoa1001294

Castro, 2015, Effect of BRCA mutations on metastatic relapse and cause-specific survival after radical treatment of localised prostate cancer, Eur Urol, 68, 186, 10.1016/j.eururo.2014.10.022

Narod, 2008, Rapid progression of prostate cancer in men with a BRCA2 mutation, Br J Cancer, 99, 371, 10.1038/sj.bjc.6604453

Hussaini, 2017, Impact of an alternative steroid on the relative bioavailability and bioequivalence of a novel versus the originator formulation of abiraterone acetate, Cancer Chemother Pharmacol, 80, 479, 10.1007/s00280-017-3360-3

He, 2017, Validation of a contemporary five-tiered Gleason grade grouping using population-based data, Eur Urol, 71, 760, 10.1016/j.eururo.2016.11.031

Khoo, 2005, Radiotherapeutic techniques for prostate cancer, dose escalation and brachytherapy, Clin Oncol (R Coll Radiol), 17, 560, 10.1016/j.clon.2005.07.006

D’Amico, 1998, Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer, JAMA, 280, 969, 10.1001/jama.280.11.969

Thorne, 2011, Decreased prostate cancer-specific survival of men with BRCA2 mutations from multiple breast cancer families, Cancer Prev Res (Phila), 4, 1002, 10.1158/1940-6207.CAPR-10-0397

Kattan, 2003, Counseling men with prostate cancer: a nomogram for predicting the presence of small, moderately differentiated, confined tumors, J Urol, 170, 1792, 10.1097/01.ju.0000091806.70171.41

Zumsteg, 2013, A new risk classification system for therapeutic decision making with intermediate-risk prostate cancer patients undergoing dose-escalated external-beam radiation therapy, Eur Urol, 64, 895, 10.1016/j.eururo.2013.03.033

Kellokumpu-Lehtinen, 2013, 2-Weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial, Lancet Oncol, 14, 117, 10.1016/S1470-2045(12)70537-5

Fizazi, 2012, Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study, Lancet Oncol, 13, 983, 10.1016/S1470-2045(12)70379-0

Kote-Jarai, 2015, Prevalence of the HOXB13 G84E germline mutation in British men and correlation with prostate cancer risk, tumour characteristics and clinical outcomes, Ann Oncol, 26, 756, 10.1093/annonc/mdv004

Tulinius, 2002, The effect of a single BRCA2 mutation on cancer in Iceland, J Med Genet, 39, 457, 10.1136/jmg.39.7.457

de Bono, 2010, Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial, Lancet, 376, 1147, 10.1016/S0140-6736(10)61389-X

Small, 2004, Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583), J Clin Oncol, 22, 1025, 10.1200/JCO.2004.06.037

Jemal, 2015, Prostate cancer incidence and PSA testing patterns in relation to USPSTF screening recommendations, JAMA, 314, 2054, 10.1001/jama.2015.14905

Bishoff, 2014, Prognostic utility of the cell cycle progression score generated from biopsy in men treated with prostatectomy, J Urol, 192, 409, 10.1016/j.juro.2014.02.003

Langley, 2013, Cardiovascular outcomes in patients with locally advanced and metastatic prostate cancer treated with luteinising-hormone-releasing-hormone agonists or transdermal oestrogen: the randomised, phase 2 MRC PATCH trial (PR09), Lancet Oncol, 14, 306, 10.1016/S1470-2045(13)70025-1

Ford, 1994, Risks of cancer in BRCA1-mutation carriers, Lancet, 343, 692, 10.1016/S0140-6736(94)91578-4

Porter, 2017, Systematic review links the prevalence of intraductal carcinoma of the prostate to prostate cancer risk categories, Eur Urol, 72, 492, 10.1016/j.eururo.2017.03.013

Lu-Yao, 2014, Fifteen-year survival outcomes following primary androgen-deprivation therapy for localized prostate cancer, JAMA Intern Med, 174, 1460, 10.1001/jamainternmed.2014.3028

Epstein, 2016, The 2014 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma: definition of grading patterns and proposal for a new grading system, Am J Surg Pathol, 40, 244, 10.1097/PAS.0000000000000530

Helgason, 2015, Loss-of-function variants in ATM confer risk of gastric cancer, Nat Genet, 47, 906, 10.1038/ng.3342

Latham, 2019, Microsatellite instability is associated with the presence of Lynch syndrome pan-cancer, J Clin Oncol, 37, 286, 10.1200/JCO.18.00283

Hussain, 2018, Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer, N Engl J Med, 378, 2465, 10.1056/NEJMoa1800536

Hu, Clinical utility of gene expression classifiers in men with newly diagnosed prostate cancer [published online, October 19, 2018], JCO Precis Oncol

Seipel, 2017, Genetic profile of ductal adenocarcinoma of the prostate, Hum Pathol, 69, 1, 10.1016/j.humpath.2017.04.015

Klotz, 2015, Nadir testosterone within first year of androgen-deprivation therapy (ADT) predicts for time to castration-resistant progression: a secondary analysis of the PR-7 trial of intermittent versus continuous ADT, J Clin Oncol, 33, 1151, 10.1200/JCO.2014.58.2973

Kaufman, 2015, Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation, J Clin Oncol, 33, 244, 10.1200/JCO.2014.56.2728

Nicolosi, Prevalence of germline variants in prostate cancer and implications for current genetic testing guidelines [published online February 7, 2019], JAMA Oncol

Yamoah, 2015, Novel biomarker signature that may predict aggressive disease in African American men with prostate cancer, J Clin Oncol, 33, 2789, 10.1200/JCO.2014.59.8912

Attard, 2010, Abiraterone acetate is well tolerated without concomitant use of corticosteroids, J Clin Oncol, 28, e560, 10.1200/JCO.2010.29.5170

Kattan, 1999, Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer, J Clin Oncol, 17, 1499, 10.1200/JCO.1999.17.5.1499

Reid, 2010, Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate, J Clin Oncol, 28, 1489, 10.1200/JCO.2009.24.6819

Delahunt, 2015, Validation of International Society of Urological Pathology (ISUP) grading for prostatic adenocarcinoma in thin core biopsies using TROG 03.04 ‘RADAR’ trial clinical data, Pathology, 47, 520, 10.1097/PAT.0000000000000318

Schweizer, 2016, Mismatch repair deficiency may be common in ductal adenocarcinoma of the prostate, Oncotarget, 7, 82504, 10.18632/oncotarget.12697

Kantoff, 2010, Sipuleucel-T immunotherapy for castration-resistant prostate cancer, N Engl J Med, 363, 411, 10.1056/NEJMoa1001294

McLeod, 2006, The bicalutamide 150 mg early prostate cancer program: findings of the North American trial at 7.7-year median followup, J Urol, 176, 75, 10.1016/S0022-5347(06)00495-2

Karnes, 2013, Validation of a genomic classifier that predicts metastasis following radical prostatectomy in an at risk patient population, J Urol, 190, 2047, 10.1016/j.juro.2013.06.017

Gallagher, 2010, Germline BRCA mutations denote a clinicopathologic subset of prostate cancer, Clin Cancer Res, 16, 2115, 10.1158/1078-0432.CCR-09-2871

Spratt, 2018, Development and validation of a novel integrated clinical-genomic risk group classification for localized prostate cancer, J Clin Oncol, 36, 581, 10.1200/JCO.2017.74.2940

Saad, 2002, A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma, J Natl Cancer Inst, 94, 1458, 10.1093/jnci/94.19.1458

Graefen, 2001, A validated strategy for side specific prediction of organ confined prostate cancer: a tool to select for nerve sparing radical prostatectomy, J Urol, 165, 857, 10.1016/S0022-5347(05)66544-5

Hempelmann, 2018, Microsatellite instability in prostate cancer by PCR or next-generation sequencing, J Immunother Cancer, 6, 29, 10.1186/s40425-018-0341-y

Pritchard, 2016, Inherited DNA-repair gene mutations in men with metastatic prostate cancer, N Engl J Med, 375, 443, 10.1056/NEJMoa1603144

Imyanitov, 2011, Drug therapy for hereditary cancers, Hered Cancer Clin Pract, 9, 5, 10.1186/1897-4287-9-5

Reese, 2012, Contemporary evaluation of the National Comprehensive Cancer Network prostate cancer risk classification system, Urology, 80, 1075, 10.1016/j.urology.2012.07.040

Pilié, 2017, Germline genetic variants in men with prostate cancer and one or more additional cancers, Cancer, 123, 3925, 10.1002/cncr.30817

Mohler, 2004, The androgen axis in recurrent prostate cancer, Clin Cancer Res, 10, 440, 10.1158/1078-0432.CCR-1146-03

Chi, 2018, Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial, Lancet Oncol, 19, 194, 10.1016/S1470-2045(17)30911-7

Gandaglia, 2019, A novel nomogram to identify candidates for extended pelvic lymph node dissection among patients with clinically localized prostate cancer diagnosed with magnetic resonance imaging-targeted and systematic biopsies, Eur Urol, 75, 506, 10.1016/j.eururo.2018.10.012

Dearnaley, 1999, Comparison of radiation side-effects of conformal and conventional radiotherapy in prostate cancer: a randomised trial, Lancet, 353, 267, 10.1016/S0140-6736(98)05180-0

Houston, 2018, Trends in prostate cancer incidence rates and prevalence of prostate-specific antigen screening by socioeconomic status and regions in the US, 2004-2013, J Urol, 199, 676, 10.1016/j.juro.2017.09.103

ERLEADATM, 2018, apalutamide tablets for oral use Horsham PA Products LP Available at https www accessdata fda gov drugsatfda docs label lbl pdf Accessed, 15, 000

Mateo, 2015, DNA-repair defects and olaparib in metastatic prostate cancer, N Engl J Med, 373, 1697, 10.1056/NEJMoa1506859

Pomerantz, 2017, The association between germline BRCA2 variants and sensitivity to platinum-based chemotherapy among men with metastatic prostate cancer, Cancer, 123, 3532, 10.1002/cncr.30808

D’Amico, 1999, Pretreatment nomogram for prostate-specific antigen recurrence after radical prostatectomy or external-beam radiation therapy for clinically localized prostate cancer, J Clin Oncol, 17, 168, 10.1200/JCO.1999.17.1.168

Klein, 2015, A genomic classifier improves prediction of metastatic disease within 5 years after surgery in node-negative high-risk prostate cancer patients managed by radical prostatectomy without adjuvant therapy, Eur Urol, 67, 778, 10.1016/j.eururo.2014.10.036

Siegel, 2017, Cancer Statistics, 2017, CA Cancer J Clin, 67, 7, 10.3322/caac.21387

Tosoian, 2017, Prognostic utility of biopsy-derived cell cycle progression score in patients with National Comprehensive Cancer Network low-risk prostate cancer undergoing radical prostatectomy: implications for treatment guidance, BJU Int, 120, 808, 10.1111/bju.13911

Cuzick, 2012, Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort, Br J Cancer, 106, 1095, 10.1038/bjc.2012.39

Schulze, 1990, Influence of different types of antiandrogens on luteinizing hormone-releasing hormone analogue-induced testosterone surge in patients with metastatic carcinoma of the prostate, J Urol, 144, 934, 10.1016/S0022-5347(17)39625-8

Wong, 2015, Evaluation of models predicting insignificant prostate cancer to select men for active surveillance of prostate cancer, Prostate Cancer Prostatic Dis, 18, 137, 10.1038/pcan.2015.1

Hussain, 2018, Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer, N Engl J Med, 378, 2465, 10.1056/NEJMoa1800536

Negoita, 2018, Annual report to the nation on the status of cancer, part II: recent changes in prostate cancer trends and disease characteristics, Cancer, 124, 2801, 10.1002/cncr.31549

Cheng, 2016, Biallelic inactivation of BRCA2 in platinum-sensitive metastatic castration-resistant prostate cancer, Eur Urol, 69, 992, 10.1016/j.eururo.2015.11.022

Wu, 2018, A comprehensive evaluation of CHEK2 germline mutations in men with prostate cancer, Prostate, 78, 607, 10.1002/pros.23505

Fizazi, 2014, Effect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration-resistant prostate cancer: results from the randomised, phase 3 AFFIRM trial, Lancet Oncol, 15, 1147, 10.1016/S1470-2045(14)70303-1

Maurice, 2016, Current status of prostate cancer diagnosis and management in the United States, JAMA Oncol, 2, 1505, 10.1001/jamaoncol.2016.1785

He, 2017, Validation of a contemporary five-tiered Gleason grade grouping using population-based data, Eur Urol, 71, 760, 10.1016/j.eururo.2016.11.031

Näslund-Koch, 2016, Increased risk for other cancers in addition to breast cancer for CHEK2*1100delC heterozygotes estimated from the Copenhagen General Population Study, J Clin Oncol, 34, 1208, 10.1200/JCO.2015.63.3594

Loblaw, 2007, Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline, J Clin Oncol, 25, 1596, 10.1200/JCO.2006.10.1949

Leyh-Bannurah, 2017, A proposal of a new nomogram for predicting upstaging in contemporary D’Amico low-risk prostate cancer patients, World J Urol, 35, 189, 10.1007/s00345-016-1863-x

Duchesne, 2016, Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial, Lancet Oncol, 17, 727, 10.1016/S1470-2045(16)00107-8

Latham, 2019, Microsatellite instability is associated with the presence of Lynch syndrome pan-cancer, J Clin Oncol, 37, 286, 10.1200/JCO.18.00283

USPSTF, 2018, cancer Screening The US Preventive Services Task Force Available at https www uspreventiveservicestaskforce org Page Document UpdateSummaryFinal prostate cancer screening ds s prostate Accessed, Prostate, 15, 1

Albertsen, 2014, Cardiovascular morbidity associated with gonadotropin releasing hormone agonists and an antagonist, Eur Urol, 65, 565, 10.1016/j.eururo.2013.10.032

Hussain, 2006, Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162), J Clin Oncol, 24, 3984, 10.1200/JCO.2006.06.4246

James, 2016, Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial, Lancet, 387, 1163, 10.1016/S0140-6736(15)01037-5

Oh, 2004, Prospective, multicenter, randomized phase II trial of the herbal supplement, PC-SPES, and diethylstilbestrol in patients with androgen-independent prostate cancer, J Clin Oncol, 22, 3705, 10.1200/JCO.2004.10.195

Clarke, 2018, Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial, Lancet Oncol, 19, 975, 10.1016/S1470-2045(18)30365-6

Kirchhoff, 2004, BRCA mutations and risk of prostate cancer in Ashkenazi Jews, Clin Cancer Res, 10, 2918, 10.1158/1078-0432.CCR-03-0604

Tosoian, 2017, Prediction of pathological stage based on clinical stage, serum prostate-specific antigen, and biopsy Gleason score: Partin tables in the contemporary era, BJU Int, 119, 676, 10.1111/bju.13573

de Bono, 2011, Abiraterone and increased survival in metastatic prostate cancer, N Engl J Med, 364, 1995, 10.1056/NEJMoa1014618

Stephenson, 2006, Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy, J Natl Cancer Inst, 98, 715, 10.1093/jnci/djj190

McLeod, 2006, Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer, BJU Int, 97, 247, 10.1111/j.1464-410X.2005.06051.x

Fizazi, 2017, Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer, N Engl J Med, 377, 352, 10.1056/NEJMoa1704174

Erho, 2013, Discovery and validation of a prostate cancer genomic classifier that predicts early metastasis following radical prostatectomy, PLoS One, 8, e66855, 10.1371/journal.pone.0066855

van Asperen, 2005, Cancer risks in BRCA2 families: estimates for sites other than breast and ovary, J Med Genet, 42, 711, 10.1136/jmg.2004.028829

James, 2017, Abiraterone for prostate cancer not previously treated with hormone therapy, N Engl J Med, 377, 338, 10.1056/NEJMoa1702900

Lotan, 2015, PTEN loss is associated with upgrading of prostate cancer from biopsy to radical prostatectomy, Mod Pathol, 28, 128, 10.1038/modpathol.2014.85

Potters, 2010, Postoperative nomogram predicting the 9-year probability of prostate cancer recurrence after permanent prostate brachytherapy using radiation dose as a prognostic variable, Int J Radiat Oncol Biol Phys, 76, 1061, 10.1016/j.ijrobp.2009.03.031

Siegel, 2019, Cancer statistics, 2019, CA Cancer J Clin, 69, 7, 10.3322/caac.21551

Haraldsdottir, 2014, Prostate cancer incidence in males with Lynch syndrome, Genet Med, 16, 553, 10.1038/gim.2013.193

Shore, 2016, Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study, Lancet Oncol, 17, 153, 10.1016/S1470-2045(15)00518-5

Cuzick, 2013, Prognostic value of PTEN loss in men with conservatively managed localised prostate cancer, Br J Cancer, 108, 2582, 10.1038/bjc.2013.248

D’Amico, 2002, Determinants of prostate cancer-specific survival after radiation therapy for patients with clinically localized prostate cancer, J Clin Oncol, 20, 4567, 10.1200/JCO.2002.03.061

Abida, Analysis of the prevalence of microsatellite instability in prostate cancer and response to immune checkpoint blockade [published online December 27, 2018], JAMA Oncol.

Sarantopoulos, 2017, Safety and pharmacokinetics of cabazitaxel in patients with hepatic impairment: a phase I dose-escalation study, Cancer Chemother Pharmacol, 79, 339, 10.1007/s00280-016-3210-8

Wong, 2015, Evaluation of models predicting insignificant prostate cancer to select men for active surveillance of prostate cancer, Prostate Cancer Prostatic Dis, 18, 137, 10.1038/pcan.2015.1

Goldwater, 2017, Comparison of a novel formulation of abiraterone acetate vs The originator formulation in healthy male subjects: two randomized, open-label, crossover studies, Clin Pharmacokinet, 56, 803, 10.1007/s40262-017-0536-2

Dearnaley, 1999, Comparison of radiation side-effects of conformal and conventional radiotherapy in prostate cancer: a randomised trial, Lancet, 353, 267, 10.1016/S0140-6736(98)05180-0

Mathieu, 2017, Prognostic value of the new Grade Groups in Prostate Cancer: a multi-institutional European validation study, Prostate Cancer Prostatic Dis, 20, 197, 10.1038/pcan.2016.66

Fizazi, 2011, Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study, Lancet, 377, 813, 10.1016/S0140-6736(10)62344-6

Hayes, 2013, OMICS-based personalized oncology: if it is worth doing, it is worth doing well!, BMC Med, 11, 221, 10.1186/1741-7015-11-221

Turo, 2014, Diethylstilboestrol for the treatment of prostate cancer: past, present and future, Scand J Urol, 48, 4, 10.3109/21681805.2013.861508

Kirchhoff, 2004, BRCA mutations and risk of prostate cancer in Ashkenazi Jews, Clin Cancer Res, 10, 2918, 10.1158/1078-0432.CCR-03-0604

Karnes, 2018, Validation of a genomic risk classifier to predict prostate cancer-specific mortality in men with adverse pathologic features, Eur Urol, 73, 168, 10.1016/j.eururo.2017.03.036

Kellokumpu-Lehtinen, 2013, 2-Weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial, Lancet Oncol, 14, 117, 10.1016/S1470-2045(12)70537-5

Struewing, 1997, The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews, N Engl J Med, 336, 1401, 10.1056/NEJM199705153362001

Cuzick, 2015, Validation of an RNA cell cycle progression score for predicting death from prostate cancer in a conservatively managed needle biopsy cohort, Br J Cancer, 113, 382, 10.1038/bjc.2015.223

Zavaski, 2016, Differences in prostate-specific antigen testing among urologists and primary care physicians following the 2012 USPSTF recommendations, JAMA Intern Med, 176, 546, 10.1001/jamainternmed.2015.7901

Pompe, 2017, Population-based validation of the 2014 ISUP Gleason grade groups in patients treated with radical prostatectomy, brachytherapy, external beam radiation, or no local treatment, Prostate, 77, 686, 10.1002/pros.23316

D’Amico, 2003, Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy, J Natl Cancer Inst, 95, 1376, 10.1093/jnci/djg043

Hayes, 2013, OMICS-based personalized oncology: if it is worth doing, it is worth doing well!, BMC Med, 11, 221, 10.1186/1741-7015-11-221

Gandaglia, 2017, Are all grade group 4 prostate cancers created equal? Implications for the applicability of the novel grade grouping, Urol Oncol, 35, 461.e7, 10.1016/j.urolonc.2017.02.012

Ondracek, 2016, Validation of the Kattan nomogram for prostate cancer recurrence after radical prostatectomy, J Natl Compr Canc Netw, 14, 1395, 10.6004/jnccn.2016.0149

Castro, 2019, PROREPAIR-B: a prospective cohort study of the impact of germline DNA repair mutations on the outcomes of patients with metastatic castration-resistant prostate cancer, J Clin Oncol, 37, 490, 10.1200/JCO.18.00358

Lecarpentier, 2017, Prediction of breast and prostate cancer risks in male BRCA1 and BRCA2 mutation carriers using polygenic risk scores, J Clin Oncol, 35, 2240, 10.1200/JCO.2016.69.4935

Isaacsson Velho, 2018, Intraductal/ductal histology and lymphovascular invasion are associated with germline DNA-repair gene mutations in prostate cancer, Prostate, 78, 401, 10.1002/pros.23484

Gandaglia, 2017, Development and internal validation of a novel model to identify the candidates for extended pelvic lymph node dissection in prostate cancer, Eur Urol, 72, 632, 10.1016/j.eururo.2017.03.049

Tarassoff, 2003, Avascular necrosis of the jaws: risk factors in metastatic cancer patients, J Oral Maxillofac Surg, 61, 1238, 10.1016/j.joms.2003.09.001

Smith, 2018, Apalutamide treatment and metastasis-free survival in prostate cancer, N Engl J Med, 378, 1408, 10.1056/NEJMoa1715546

Dijkstra, 2016, The AVOCAT study: bicalutamide monotherapy versus combined bicalutamide plus dutasteride therapy for patients with locally advanced or metastatic carcinoma of the prostate-a long-term follow-up comparison and quality of life analysis, Springerplus, 5, 653, 10.1186/s40064-016-2280-8

Cooperberg, 2015, Combined value of validated clinical and genomic risk stratification tools for predicting prostate cancer mortality in a high-risk prostatectomy cohort, Eur Urol, 67, 326, 10.1016/j.eururo.2014.05.039

Castro, 2013, Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer, J Clin Oncol, 31, 1748, 10.1200/JCO.2012.43.1882

Lotan, 2015, PTEN loss is associated with upgrading of prostate cancer from biopsy to radical prostatectomy, Mod Pathol, 28, 128, 10.1038/modpathol.2014.85

Jansson, 2018, Concordance of non-low-risk disease among pairs of brothers with prostate cancer, J Clin Oncol, 36, 1847, 10.1200/JCO.2017.76.6907

Scher, 2012, Increased survival with enzalutamide in prostate cancer after chemotherapy, N Engl J Med, 367, 1187, 10.1056/NEJMoa1207506

Robinson, 2015, Integrative clinical genomics of advanced prostate cancer, Cell, 161, 1215, 10.1016/j.cell.2015.05.001

Mitra, 2008, Prostate cancer in male BRCA1 and BRCA2 mutation carriers has a more aggressive phenotype, Br J Cancer, 98, 502, 10.1038/sj.bjc.6604132

Van Den Eeden, 2018, A biopsy-based 17-gene genomic prostate score as a predictor of metastases and prostate cancer death in surgically treated men with clinically localized disease, Eur Urol, 73, 129, 10.1016/j.eururo.2017.09.013

Kohler, 2015, Annual report to the nation on the status of cancer, 1975-2011, featuring incidence of breast cancer subtypes by race/ethnicity, poverty, and state, J Natl Cancer Inst, 107, djv048, 10.1093/jnci/djv048

Epstein, 2016, A contemporary prostate cancer grading system: a validated alternative to the Gleason score, Eur Urol, 69, 428, 10.1016/j.eururo.2015.06.046

Cheng, 2016, Biallelic inactivation of BRCA2 in platinum-sensitive metastatic castration-resistant prostate cancer, Eur Urol, 69, 992, 10.1016/j.eururo.2015.11.022

Jansson, 2018, Concordance of non-low-risk disease among pairs of brothers with prostate cancer, J Clin Oncol, 36, 1847, 10.1200/JCO.2017.76.6907

Punnen, 2014, Multi-institutional validation of the CAPRA-S score to predict disease recurrence and mortality after radical prostatectomy, Eur Urol, 65, 1171, 10.1016/j.eururo.2013.03.058

Stephenson, 2009, Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era, J Clin Oncol, 27, 4300, 10.1200/JCO.2008.18.2501

D’Amico, 2002, Determinants of prostate cancer-specific survival after radiation therapy for patients with clinically localized prostate cancer, J Clin Oncol, 20, 4567, 10.1200/JCO.2002.03.061

Samson, 2002, Systematic review and meta-analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma, Cancer, 95, 361, 10.1002/cncr.10647

McLeod, 2006, Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer, BJU Int, 97, 247, 10.1111/j.1464-410X.2005.06051.x

Freedland, 2016, Utilization of a genomic classifier for prediction of metastasis following salvage radiation therapy after radical prostatectomy, Eur Urol, 70, 588, 10.1016/j.eururo.2016.01.008

Fisher, 2013, Prognostic value of Ki-67 for prostate cancer death in a conservatively managed cohort, Br J Cancer, 108, 271, 10.1038/bjc.2012.598

Li, 2004, Ki-67 staining index predicts distant metastasis and survival in locally advanced prostate cancer treated with radiotherapy: an analysis of patients in radiation therapy oncology group protocol 86-10, Clin Cancer Res, 10, 4118, 10.1158/1078-0432.CCR-1052-03

Petrylak, 2004, Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer, N Engl J Med, 351, 1513, 10.1056/NEJMoa041318

Szmulewitz, 2018, Prospective international randomized phase II study of low-dose abiraterone with food versus standard dose abiraterone in castration-resistant prostate cancer, J Clin Oncol, 36, 1389, 10.1200/JCO.2017.76.4381

Ewing, 2012, Germline mutations in HOXB13 and prostate-cancer risk, N Engl J Med, 366, 141, 10.1056/NEJMoa1110000

Ondracek, 2016, Validation of the Kattan nomogram for prostate cancer recurrence after radical prostatectomy, J Natl Compr Canc Netw, 14, 1395, 10.6004/jnccn.2016.0149

Punnen, 2014, Multi-institutional validation of the CAPRA-S score to predict disease recurrence and mortality after radical prostatectomy, Eur Urol, 65, 1171, 10.1016/j.eururo.2013.03.058

Albright, 2015, Prostate cancer risk prediction based on complete prostate cancer family history, Prostate, 75, 390, 10.1002/pros.22925

Kattan, 1999, Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer, J Clin Oncol, 17, 1499, 10.1200/JCO.1999.17.5.1499

Spratt, 2018, Development and validation of a novel integrated clinical-genomic risk group classification for localized prostate cancer, J Clin Oncol, 36, 581, 10.1200/JCO.2017.74.2940

Barocas, 2015, Effect of the USPSTF grade D recommendation against screening for prostate cancer on incident prostate cancer diagnoses in the United States, J Urol, 194, 1587, 10.1016/j.juro.2015.06.075

Bishoff, 2014, Prognostic utility of the cell cycle progression score generated from biopsy in men treated with prostatectomy, J Urol, 192, 409, 10.1016/j.juro.2014.02.003

Mitra, 2008, Prostate cancer in male BRCA1 and BRCA2 mutation carriers has a more aggressive phenotype, Br J Cancer, 98, 502, 10.1038/sj.bjc.6604132

Zhou, 2018, High-grade prostatic intraepithelial neoplasia, PIN-like carcinoma, ductal carcinoma, and intraductal carcinoma of the prostate, Mod Pathol, 31, S71, 10.1038/modpathol.2017.138

Freedland, 2016, Utilization of a genomic classifier for prediction of metastasis following salvage radiation therapy after radical prostatectomy, Eur Urol, 70, 588, 10.1016/j.eururo.2016.01.008

Wu, 2018, A comprehensive evaluation of CHEK2 germline mutations in men with prostate cancer, Prostate, 78, 607, 10.1002/pros.23505

Khor, 2009, MDM2 and Ki-67 predict for distant metastasis and mortality in men treated with radiotherapy and androgen deprivation for prostate cancer: RTOG 92-02, J Clin Oncol, 27, 3177, 10.1200/JCO.2008.19.8267

Penson, 2016, Enzalutamide versus bicalutamide in castration-resistant prostate cancer: the STRIVE trial, J Clin Oncol, 34, 2098, 10.1200/JCO.2015.64.9285

Moran, 2012, Risk of cancer other than breast or ovarian in individuals with BRCA1 and BRCA2 mutations, Fam Cancer, 11, 235, 10.1007/s10689-011-9506-2

Sweeney, 2015, Chemohormonal therapy in metastatic hormone-sensitive prostate cancer, N Engl J Med, 373, 737, 10.1056/NEJMoa1503747

Mersch, 2015, Cancers associated with BRCA1 and BRCA2 mutations other than breast and ovarian, Cancer, 121, 269, 10.1002/cncr.29041

Dell’Oglio, 2016, Predicting survival of men with recurrent prostate cancer after radical prostatectomy, Eur J Cancer, 54, 27, 10.1016/j.ejca.2015.11.004

Zhao, 2016, Development and validation of a 24-gene predictor of response to postoperative radiotherapy in prostate cancer: a matched, retrospective analysis, Lancet Oncol, 17, 1612, 10.1016/S1470-2045(16)30491-0

Na, 2017, Germline mutations in ATM and BRCA1/2 distinguish risk for lethal and indolent prostate cancer and are associated with early age at death, Eur Urol, 71, 740, 10.1016/j.eururo.2016.11.033

Fizazi, 2015, Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial, Lancet Oncol, 16, 787, 10.1016/S1470-2045(15)00011-X

Cuzick, 2015, Validation of an RNA cell cycle progression score for predicting death from prostate cancer in a conservatively managed needle biopsy cohort, Br J Cancer, 113, 382, 10.1038/bjc.2015.223

Maurice, 2015, Contemporary nationwide patterns of active surveillance use for prostate cancer, JAMA Intern Med, 175, 1569, 10.1001/jamainternmed.2015.2835

Nicolosi, Prevalence of germline variants in prostate cancer and implications for current genetic testing guidelines [published online February 7, 2019], JAMA Oncol

Kearns, 2018, PSA screening, prostate biopsy, and treatment of prostate cancer in the years surrounding the USPSTF recommendation against prostate cancer screening, Cancer, 124, 2733, 10.1002/cncr.31337

Mateo, 2015, DNA-repair defects and olaparib in metastatic prostate cancer, N Engl J Med, 373, 1697, 10.1056/NEJMoa1506859

Spratt, 2017, Individual patient-level meta-analysis of the performance of the Decipher genomic classifier in high-risk men after prostatectomy to predict development of metastatic disease, J Clin Oncol, 35, 1991, 10.1200/JCO.2016.70.2811

Bahl, 2013, Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial, Ann Oncol, 24, 2402, 10.1093/annonc/mdt194

Steuber, 2006, Validation of a nomogram for prediction of side specific extracapsular extension at radical prostatectomy, J Urol, 175, 939, 10.1016/S0022-5347(05)00342-3

Graff, 2016, Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer, Oncotarget, 7, 52810, 10.18632/oncotarget.10547

Erkko, 2007, A recurrent mutation in PALB2 in Finnish cancer families, Nature, 446, 316, 10.1038/nature05609

Albright, 2015, Prostate cancer risk prediction based on complete prostate cancer family history, Prostate, 75, 390, 10.1002/pros.22925

Cagiannos, 2003, A preoperative nomogram identifying decreased risk of positive pelvic lymph nodes in patients with prostate cancer, J Urol, 170, 1798, 10.1097/01.ju.0000091805.98960.13

Reese, 2012, Contemporary evaluation of the National Comprehensive Cancer Network prostate cancer risk classification system, Urology, 80, 1075, 10.1016/j.urology.2012.07.040

Eggener, 2019, A 17-gene panel for prediction of adverse prostate cancer pathologic features: Prospective clinical validation and utility, Urology, 126, 76, 10.1016/j.urology.2018.11.050

Chua, 2017, A prostate cancer “nimbosus”: genomic instability and SChLAP1 dysregulation underpin aggression of intraductal and cribriform subpathologies, Eur Urol, 72, 665, 10.1016/j.eururo.2017.04.034

Potters, 2008, 12-year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer, J Urol, 179, S20, 10.1016/j.juro.2008.03.133

Kattan, 2001, Pretreatment nomogram for predicting freedom from recurrence after permanent prostate brachytherapy in prostate cancer, Urology, 58, 393, 10.1016/S0090-4295(01)01233-X

Isaacsson Velho, 2018, Intraductal/ductal histology and lymphovascular invasion are associated with germline DNA-repair gene mutations in prostate cancer, Prostate, 78, 401, 10.1002/pros.23484

Antonarakis, 2018, Germline DNA-repair gene mutations and outcomes in men with metastatic castration-resistant prostate cancer receiving first-line abiraterone and enzalutamide, Eur Urol, 74, 218, 10.1016/j.eururo.2018.01.035

Ford, 1994, Risks of cancer in BRCA1-mutation carriers, Lancet, 343, 692, 10.1016/S0140-6736(94)91578-4

Klein, 2017, Molecular analysis of low grade prostate cancer using a genomic classifier of metastatic potential, J Urol, 197, 122, 10.1016/j.juro.2016.08.091

Attard, 2010, Abiraterone acetate is well tolerated without concomitant use of corticosteroids, J Clin Oncol, 28, e560, 10.1200/JCO.2010.29.5170

Mateo, 2018, Clinical outcome of prostate cancer patients with germline DNA repair mutations: Retrospective analysis from an international study, Eur Urol, 73, 687, 10.1016/j.eururo.2018.01.010

Brand, 2016, Patient-specific meta-analysis of 2 clinical validation studies to predict pathologic outcomes in prostate cancer using the 17-gene genomic prostate score, Urology, 89, 69, 10.1016/j.urology.2015.12.008

Kyriakopoulos, 2018, Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: Long-term survival analysis of the randomized phase III E3805 CHAARTED trial, J Clin Oncol, 36, 1080, 10.1200/JCO.2017.75.3657

Tannock, 2004, Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer, N Engl J Med, 351, 1502, 10.1056/NEJMoa040720

Sinnott, 2017, Prognostic utility of a new mRNA expression signature of Gleason score, Clin Cancer Res, 23, 81, 10.1158/1078-0432.CCR-16-1245

Meisel, 2016, Severe neutropenia during cabazitaxel treatment is associated with survival benefit in men with metastatic castration-resistant prostate cancer (mCRPC): a post-hoc analysis of the TROPIC phase III trial, Eur J Cancer, 56, 93, 10.1016/j.ejca.2015.12.009

Verhoven, 2013, Ki-67 is an independent predictor of metastasis and cause-specific mortality for prostate cancer patients treated on Radiation Therapy Oncology Group (RTOG) 94-08, Int J Radiat Oncol Biol Phys, 86, 317, 10.1016/j.ijrobp.2013.01.016

Na, 2017, Germline mutations in ATM and BRCA1/2 distinguish risk for lethal and indolent prostate cancer and are associated with early age at death, Eur Urol, 71, 740, 10.1016/j.eururo.2016.11.033

Moyer, 2012, Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement, Ann Intern Med, 157, 120, 10.7326/0003-4819-157-2-201207170-00459

Ockrim, 2003, Transdermal estradiol therapy for advanced prostate cancer--forward to the past?, J Urol, 169, 1735, 10.1097/01.ju.0000061024.75334.40

Stephenson, 2009, Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era, J Clin Oncol, 27, 4300, 10.1200/JCO.2008.18.2501

Struewing, 1997, The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews, N Engl J Med, 336, 1401, 10.1056/NEJM199705153362001

Dinh, 2015, Incidence and predictors of upgrading and up staging among 10,000 contemporary patients with low risk prostate cancer, J Urol, 194, 343, 10.1016/j.juro.2015.02.015

Klein, 2017, Molecular analysis of low grade prostate cancer using a genomic classifier of metastatic potential, J Urol, 197, 122, 10.1016/j.juro.2016.08.091

Steuber, 2006, Validation of a nomogram for prediction of side specific extracapsular extension at radical prostatectomy, J Urol, 175, 939, 10.1016/S0022-5347(05)00342-3

Womble, 2015, Contemporary use of initial active surveillance among men in Michigan with low-risk prostate cancer, Eur Urol, 67, 44, 10.1016/j.eururo.2014.08.024

Freedland, 2013, Prognostic utility of cell cycle progression score in men with prostate cancer after primary external beam radiation therapy, Int J Radiat Oncol Biol Phys, 86, 848, 10.1016/j.ijrobp.2013.04.043

Hager, 2016, Anti-tumour activity of platinum compounds in advanced prostate cancer-a systematic literature review, Ann Oncol, 27, 975, 10.1093/annonc/mdw156

Agalliu, 2009, Associations of high-grade prostate cancer with BRCA1 and BRCA2 founder mutations, Clin Cancer Res, 15, 1112, 10.1158/1078-0432.CCR-08-1822

Kelly, 2017, Past, current, and future incidence rates and burden of metastatic prostate cancer in the United States, Eur Urol Focus, 71, 195, 10.1016/j.eururo.2016.05.011

Le, 2017, Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade, Science, 357, 409, 10.1126/science.aan6733

Muralidhar, 2015, Definition and validation of “favorable high-risk prostate cancer”: implications for personalizing treatment of radiation-managed patients, Int J Radiat Oncol Biol Phys, 93, 828, 10.1016/j.ijrobp.2015.07.2281

Leongamornlert, 2012, Germline BRCA1 mutations increase prostate cancer risk, Br J Cancer, 106, 1697, 10.1038/bjc.2012.146

Troyer, 2015, A multicenter study shows PTEN deletion is strongly associated with seminal vesicle involvement and extracapsular extension in localized prostate cancer, Prostate, 75, 1206, 10.1002/pros.23003

Fizazi, 2017, Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer, N Engl J Med, 377, 352, 10.1056/NEJMoa1704174

Ryan, 2015, Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study, Lancet Oncol, 16, 152, 10.1016/S1470-2045(14)71205-7

Erkko, 2007, A recurrent mutation in PALB2 in Finnish cancer families, Nature, 446, 316, 10.1038/nature05609

Drazer, 2015, National prostate cancer screening rates after the 2012 US Preventive Services Task Force recommendation discouraging prostate-specific antigen-based screening, J Clin Oncol, 33, 2416, 10.1200/JCO.2015.61.6532

Briganti, 2007, A nomogram for staging of exclusive nonobturator lymph node metastases in men with localized prostate cancer, Eur Urol, 51, 112, 10.1016/j.eururo.2006.05.045

Schweizer, 2016, Mismatch repair deficiency may be common in ductal adenocarcinoma of the prostate, Oncotarget, 7, 82504, 10.18632/oncotarget.12697

Hager, 2016, Anti-tumour activity of platinum compounds in advanced prostate cancer-a systematic literature review, Ann Oncol, 27, 975, 10.1093/annonc/mdw156

Saad, 2004, Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer, J Natl Cancer Inst, 96, 879, 10.1093/jnci/djh141

Kaufman, 2015, Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation, J Clin Oncol, 33, 244, 10.1200/JCO.2014.56.2728

Epstein, 2016, A contemporary prostate cancer grading system: a validated alternative to the Gleason score, Eur Urol, 69, 428, 10.1016/j.eururo.2015.06.046

Le, 2017, Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade, Science, 357, 409, 10.1126/science.aan6733

Lotan, 2016, Analytic validation of a clinical-grade PTEN immunohistochemistry assay in prostate cancer by comparison with PTEN FISH, Mod Pathol, 29, 904, 10.1038/modpathol.2016.88

Ewing, 2012, Germline mutations in HOXB13 and prostate-cancer risk, N Engl J Med, 366, 141, 10.1056/NEJMoa1110000

McLeod, 2006, The bicalutamide 150 mg early prostate cancer program: findings of the North American trial at 7.7-year median followup, J Urol, 176, 75, 10.1016/S0022-5347(06)00495-2

Thorne, 2011, Decreased prostate cancer-specific survival of men with BRCA2 mutations from multiple breast cancer families, Cancer Prev Res (Phila), 4, 1002, 10.1158/1940-6207.CAPR-10-0397

Potters, 2008, 12-year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer, J Urol, 179, S20, 10.1016/j.juro.2008.03.133

Kim, Validation of the Decipher Test for predicting adverse pathology in candidates for prostate cancer active surveillance [published online December 12, 2018], Prostate Cancer Prostatic Dis.

Böttcher, 2018, Cribriform and intraductal prostate cancer are associated with increased genomic instability and distinct genomic alterations, BMC Cancer, 18, 8, 10.1186/s12885-017-3976-z

Hu, Clinical utility of gene expression classifiers in men with newly diagnosed prostate cancer [published online, October 19, 2018], JCO Precis Oncol

Antonarakis, 2019, Clinical features and therapeutic outcomes in men with advanced prostate cancer and DNA mismatch repair gene mutations, Eur Urol, 75, 378, 10.1016/j.eururo.2018.10.009

Etzioni, 2016, Recent trends in PSA testing and prostate cancer incidence: a look at context, JAMA Oncol, 2, 955, 10.1001/jamaoncol.2015.6310

Gallagher, 2010, Germline BRCA mutations denote a clinicopathologic subset of prostate cancer, Clin Cancer Res, 16, 2115, 10.1158/1078-0432.CCR-09-2871

Lu-Yao, 2014, Fifteen-year survival outcomes following primary androgen-deprivation therapy for localized prostate cancer, JAMA Intern Med, 174, 1460, 10.1001/jamainternmed.2014.3028

Attard, 2009, Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer, J Clin Oncol, 27, 3742, 10.1200/JCO.2008.20.0642

Womble, 2015, Contemporary use of initial active surveillance among men in Michigan with low-risk prostate cancer, Eur Urol, 67, 44, 10.1016/j.eururo.2014.08.024

Tomlins, 2015, Characterization of 1577 primary prostate cancers reveals novel biological and clinicopathologic insights into molecular subtypes, Eur Urol, 68, 555, 10.1016/j.eururo.2015.04.033

Abdollah, 2014, Predicting survival of patients with node-positive prostate cancer following multimodal treatment, Eur Urol, 65, 554, 10.1016/j.eururo.2013.09.025

Labrie, 1987, Flutamide eliminates the risk of disease flare in prostatic cancer patients treated with a luteinizing hormone-releasing hormone agonist, J Urol, 138, 804, 10.1016/S0022-5347(17)43380-5

Saad, 2002, A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma, J Natl Cancer Inst, 94, 1458, 10.1093/jnci/94.19.1458

Agalliu, 2009, Associations of high-grade prostate cancer with BRCA1 and BRCA2 founder mutations, Clin Cancer Res, 15, 1112, 10.1158/1078-0432.CCR-08-1822

Kattan, 2001, Pretreatment nomogram for predicting freedom from recurrence after permanent prostate brachytherapy in prostate cancer, Urology, 58, 393, 10.1016/S0090-4295(01)01233-X

Hayes, 2013, From genome to bedside: are we lost in translation?, Breast, 22, S22, 10.1016/j.breast.2013.07.004

Erho, 2013, Discovery and validation of a prostate cancer genomic classifier that predicts early metastasis following radical prostatectomy, PLoS One, 8, e66855, 10.1371/journal.pone.0066855

Den, 2014, Genomic prostate cancer classifier predicts biochemical failure and metastases in patients after postoperative radiation therapy, Int J Radiat Oncol Biol Phys, 89, 1038, 10.1016/j.ijrobp.2014.04.052

Fedewa, 2017, Recent patterns of prostate-specific antigen testing for prostate cancer screening in the United States, JAMA Intern Med, 177, 1040, 10.1001/jamainternmed.2017.0340

Dell’Oglio, 2016, Predicting survival of men with recurrent prostate cancer after radical prostatectomy, Eur J Cancer, 54, 27, 10.1016/j.ejca.2015.11.004

Den, 2015, Genomic classifier identifies men with adverse pathology after radical prostatectomy who benefit from adjuvant radiation therapy, J Clin Oncol, 33, 944, 10.1200/JCO.2014.59.0026

Prensner, 2014, RNA biomarkers associated with metastatic progression in prostate cancer: a multi-institutional high-throughput analysis of SChLAP1, Lancet Oncol, 15, 1469, 10.1016/S1470-2045(14)71113-1

Fedewa, 2017, Recent patterns of prostate-specific antigen testing for prostate cancer screening in the United States, JAMA Intern Med, 177, 1040, 10.1001/jamainternmed.2017.0340

Bratt, 2016, Family history and probability of prostate cancer, differentiated by risk category: a nationwide population-based study, J Natl Cancer Inst, 108, 10.1093/jnci/djw110

Duchesne, 2017, Health-related quality of life for immediate versus delayed androgen-deprivation therapy in patients with asymptomatic, non-curable prostate cancer (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial, Lancet Oncol, 18, 1192, 10.1016/S1470-2045(17)30426-6

Rosenthal, Effect of chemotherapy with docetaxel with androgen suppression and radiotherapy for localized high-risk prostate cancer: the randomized phase III NRG Oncology RTOG 0521 trial [published online March 12, 2019], J Clin Oncol.

Thompson, 2002, Cancer incidence in BRCA1 mutation carriers, J Natl Cancer Inst, 94, 1358, 10.1093/jnci/94.18.1358

Leapman, 2017, Application of a prognostic Gleason grade grouping system to assess distant prostate cancer outcomes, Eur Urol, 71, 750, 10.1016/j.eururo.2016.11.032

Leongamornlert, 2012, Germline BRCA1 mutations increase prostate cancer risk, Br J Cancer, 106, 1697, 10.1038/bjc.2012.146

Zhou, 2018, High-grade prostatic intraepithelial neoplasia, PIN-like carcinoma, ductal carcinoma, and intraductal carcinoma of the prostate, Mod Pathol, 31, S71, 10.1038/modpathol.2017.138

Saad, 2018, Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trial, Lancet Oncol, 19, 1404, 10.1016/S1470-2045(18)30456-X

Cooperberg, 2013, Validation of a cell-cycle progression gene panel to improve risk stratification in a contemporary prostatectomy cohort, J Clin Oncol, 31, 1428, 10.1200/JCO.2012.46.4396

Berthold, 2008, Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study, J Clin Oncol, 26, 242, 10.1200/JCO.2007.12.4008

Eisenberger, 2017, Phase III study comparing a reduced dose of cabazitaxel (20 mg/m(2)) and the currently approved dose (25 mg/m(2)) in postdocetaxel patients with metastatic castration-resistant prostate cancer-PROSELICA, J Clin Oncol, 35, 3198, 10.1200/JCO.2016.72.1076

Robinson, 2015, Integrative clinical genomics of advanced prostate cancer, Cell, 161, 1215, 10.1016/j.cell.2015.05.001

Antonarakis, 2019, Clinical features and therapeutic outcomes in men with advanced prostate cancer and DNA mismatch repair gene mutations, Eur Urol, 75, 378, 10.1016/j.eururo.2018.10.009

Karnes, 2018, Validation of a genomic risk classifier to predict prostate cancer-specific mortality in men with adverse pathologic features, Eur Urol, 73, 168, 10.1016/j.eururo.2017.03.036

Sun, 2016, Comparison of gonadotropin-releasing hormone agonists and orchiectomy: effects of androgen-deprivation therapy, JAMA Oncol, 2, 500, 10.1001/jamaoncol.2015.4917

James, 2017, Abiraterone for prostate cancer not previously treated with hormone therapy, N Engl J Med, 377, 338, 10.1056/NEJMoa1702900

Jemal, 2015, Prostate cancer incidence and PSA testing patterns in relation to USPSTF screening recommendations, JAMA, 314, 2054, 10.1001/jama.2015.14905

Kolinsky, 2016, The ongoing challenges of targeting the androgen receptor, Eur Urol, 69, 841, 10.1016/j.eururo.2015.10.052

Hansen, 2018, Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study, Ann Oncol, 29, 1807, 10.1093/annonc/mdy232

Lee, 2006, Development and validation of a prognostic index for 4-year mortality in older adults, JAMA, 295, 801, 10.1001/jama.295.7.801

Mohler, 2004, The androgen axis in recurrent prostate cancer, Clin Cancer Res, 10, 440, 10.1158/1078-0432.CCR-1146-03

Maurice, 2016, Current status of prostate cancer diagnosis and management in the United States, JAMA Oncol, 2, 1505, 10.1001/jamaoncol.2016.1785

Kim, Validation of the Decipher Test for predicting adverse pathology in candidates for prostate cancer active surveillance [published online December 12, 2018], Prostate Cancer Prostatic Dis.

Smith, 2014, Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance), J Clin Oncol, 32, 1143, 10.1200/JCO.2013.51.6500

Ham, 2017, New prostate cancer grading system predicts long-term survival following surgery for Gleason score 8-10 prostate cancer, Eur Urol, 71, 907, 10.1016/j.eururo.2016.11.006

Middha, Reliable pan-cancer microsatellite instability assessment by using targeted next-generation sequencing data [published online October 3, 2017], JCO Precis Oncol.

Negoita, 2018, Annual report to the nation on the status of cancer, part II: recent changes in prostate cancer trends and disease characteristics, Cancer, 124, 2801, 10.1002/cncr.31549

Cher, 2017, Appropriateness criteria for active surveillance of prostate cancer, J Urol, 197, 67, 10.1016/j.juro.2016.07.005

Turo, 2014, Diethylstilboestrol for the treatment of prostate cancer: past, present and future, Scand J Urol, 48, 4, 10.3109/21681805.2013.861508

Cuzick, 2013, Prognostic value of PTEN loss in men with conservatively managed localised prostate cancer, Br J Cancer, 108, 2582, 10.1038/bjc.2013.248

Giri, 2019, Germline genetic testing for inherited prostate cancer in practice: implications for genetic testing, precision therapy, and cascade testing, Prostate, 10.1002/pros.23739

Mathieu, 2017, Prognostic value of the new Grade Groups in Prostate Cancer: a multi-institutional European validation study, Prostate Cancer Prostatic Dis, 20, 197, 10.1038/pcan.2016.66

Lotan, 2011, PTEN protein loss by immunostaining: analytic validation and prognostic indicator for a high risk surgical cohort of prostate cancer patients, Clin Cancer Res, 17, 6563, 10.1158/1078-0432.CCR-11-1244

Lotan, 2016, Analytic validation of a clinical-grade PTEN immunohistochemistry assay in prostate cancer by comparison with PTEN FISH, Mod Pathol, 29, 904, 10.1038/modpathol.2016.88

Mateo, 2018, Clinical outcome of prostate cancer patients with germline DNA repair mutations: Retrospective analysis from an international study, Eur Urol, 73, 687, 10.1016/j.eururo.2018.01.010

Dinh, 2016, Occult high-risk disease in clinically low-risk prostate cancer with ≥50% positive biopsy cores: should national guidelines stop calling them low-risk?, Urology, 87, 125, 10.1016/j.urology.2015.08.026

Giri, 2019, Germline genetic testing for inherited prostate cancer in practice: implications for genetic testing, precision therapy, and cascade testing, Prostate, 10.1002/pros.23739

Penson, 2016, Enzalutamide versus bicalutamide in castration-resistant prostate cancer: the STRIVE trial, J Clin Oncol, 34, 2098, 10.1200/JCO.2015.64.9285

Pomerantz, 2017, The association between germline BRCA2 variants and sensitivity to platinum-based chemotherapy among men with metastatic prostate cancer, Cancer, 123, 3532, 10.1002/cncr.30808

Porter, 2017, Systematic review links the prevalence of intraductal carcinoma of the prostate to prostate cancer risk categories, Eur Urol, 72, 492, 10.1016/j.eururo.2017.03.013

Hempelmann, 2018, Microsatellite instability in prostate cancer by PCR or next-generation sequencing, J Immunother Cancer, 6, 29, 10.1186/s40425-018-0341-y

Loeb, 2016, Evaluation of the 2015 Gleason grade groups in a nationwide population-based cohort, Eur Urol, 69, 1135, 10.1016/j.eururo.2015.11.036

Ohori, 2004, Predicting the presence and side of extracapsular extension: a nomogram for staging prostate cancer, J Urol, 171, 1844, 10.1097/01.ju.0000121693.05077.3d

Tendulkar, 2016, Contemporary update of a multi-institutional predictive nomogram for salvage radiotherapy after radical prostatectomy, J Clin Oncol, 34, 3648, 10.1200/JCO.2016.67.9647

Seipel, 2017, Genetic profile of ductal adenocarcinoma of the prostate, Hum Pathol, 69, 1, 10.1016/j.humpath.2017.04.015

Moyer, 2012, Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement, Ann Intern Med, 157, 120, 10.7326/0003-4819-157-2-201207170-00459

Guedes, 2017, MSH2 loss in primary prostate cancer, Clin Cancer Res, 23, 6863, 10.1158/1078-0432.CCR-17-0955

Kolinsky, 2016, The ongoing challenges of targeting the androgen receptor, Eur Urol, 69, 841, 10.1016/j.eururo.2015.10.052

van Asperen, 2005, Cancer risks in BRCA2 families: estimates for sites other than breast and ovary, J Med Genet, 42, 711, 10.1136/jmg.2004.028829

Beer, 2014, Enzalutamide in metastatic prostate cancer before chemotherapy, N Engl J Med, 371, 424, 10.1056/NEJMoa1405095